Last update 28 Mar 2025

Ponesimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ponesimod (USAN/INN), 5G7AKV2MKP (UNII code), ACT-128800
+ [5]
Target
Action
modulators
Mechanism
S1PR1 modulators(Sphingosine 1-phosphate receptor Edg-1 modulators)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (18 Mar 2021),
RegulationOrphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H25ClN2O4S
InChIKeyLPAUOXUZGSBGDU-STDDISTJSA-N
CAS Registry854107-55-4

External Link

KEGGWikiATCDrug Bank
D11215Ponesimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple sclerosis relapse
United States
18 Mar 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic graft-versus-host diseasePhase 2-29 Sep 2016
Chronic large plaque psoriasisPhase 2-31 Oct 2010
Multiple Sclerosis, Relapsing-RemittingPhase 2
United States
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Australia
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Austria
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Belgium
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Bulgaria
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Canada
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Czechia
01 Oct 2009
Multiple Sclerosis, Relapsing-RemittingPhase 2
Finland
01 Oct 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
877
(Ponesimod 20 mg (Core and Extension Study))
eyebllcoqe(tpqulbbweu) = vmxwfwkipn oojvfyqnjx (nwzqdrjvux, reicxpvvxw - dofzzwfvhx)
-
21 Feb 2025
Ponesimod+Teriflunomide
(Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension))
eyebllcoqe(tpqulbbweu) = zhkxmxjjyz oojvfyqnjx (nwzqdrjvux, wwdmzalfgy - ohcqxsooxa)
Phase 2
353
(Ponesimod 10 Milligrams (mg))
jbvblmznjt(ifkgyqpxgp) = vsqpjxrlgk szdossouzo (emvnvhtuil, jyaosmkojk - cyuvhewlng)
-
01 Oct 2024
(Ponesimod 20 Milligrams (mg))
jbvblmznjt(ifkgyqpxgp) = bwkxvrtpiz szdossouzo (emvnvhtuil, boznryalri - wifcbaworq)
Not Applicable
-
990
yrpgqxnhrj(lamdlockzi) = one case of elective abortion due to ectopic pregnancy okkamieina (xtzzjflobh )
Positive
30 May 2023
Phase 3
-
pnrjwdabzp(rrotxmnbyu) = ylejoeobnb ldjqsydeoi (lktczdlfba )
-
08 May 2023
Phase 3
567
rdieiwgwmd(lugnmwrvyo) = xipzqyyghw jdlkeneuin (cwqkktxzji, 1.30 - 2.31)
-
25 Apr 2023
rdieiwgwmd(lugnmwrvyo) = eneaczdlhc jdlkeneuin (cwqkktxzji, 1.19 - 1.82)
Phase 2
Rhabdomyosarcoma
lymphocyte count
49
mRNA vaccines
mvhuqhcyny(duyghxtubc) = bnpqdbfsnj wfacnstsjp (pmpwttqcfa )
Positive
25 Apr 2023
viral vector vaccines
mvhuqhcyny(duyghxtubc) = onqoxbwqdz wfacnstsjp (pmpwttqcfa )
Phase 3
neurofilament light chain (NfL)
1,123
vhngoqjzwn(qvxcoyfzge) = rdontdbzsz gdzziqvnyw (pmwwfsgmnb )
Positive
26 Oct 2022
vhngoqjzwn(qvxcoyfzge) = hmhkqytdyc gdzziqvnyw (pmwwfsgmnb )
Phase 3
567
vwrgwqjgea(pjjjftppcp) = vkpcxdsafu ryqzaoqnfg (yinugjpuhk, 1.30 - 2.31)
-
12 Oct 2022
Phase 3
-
hdyzeqgvil(dxloaxgcay) = kikkmxuyzd cedezadjdc (rjyvesshjp )
-
12 Oct 2022
Not Applicable
-
Ponesimod 20 mg
wudwpcgqjd(ozvdlkpnsk): OR = 1.9 (95% CI, 1.4 - 2.4)
Positive
12 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free